ReviewKidney international2022
COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment.
Review in Kidney international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 2 syntheses or guidelines pooled it, 153 citations in OpenAlex.
- CKD-related impairment in humoral and cellular immune response and potential correlation with long COVID-19: a systematic review.Frontiers in immunology · 2025Pooled it
- Autoimmune encephalitis in COVID-19 patients: a systematic review of case reports and case series.Frontiers in neurology · 2023Pooled it
- A novel machine learning framework-based rapid screening of ionizable lipids in LNPs for highly-efficient mRNA expression.Acta pharmaceutica Sinica. B · 2026Article
- Prospective Study of Treatment with Ensitrelvir for COVID-19 in Patients Undergoing Hemodialysis (PROTECT-HD).Infectious diseases and therapy · 2026Article
- Clinical Manifestations and Mortality Predictors of COVID-19 in Patients Undergoing Chronic Hemodialysis: A Retrospective Cohort Study from Romania.Journal of clinical medicine · 2026Article
- Influenza Vaccine Immunogenicity in Hemodialysis Patients.Vaccines · 2026Article
- Risk and prognosis of Omicron infection in home-based dialysis patients: a retrospective cohort study in China.BMC nephrology · 2025Article
- Long-Term Outcomes of COVID-19 in Patients Receiving Maintenance Dialysis: A Propensity Score Matched Population-Based Cohort Study.Kidney360 · 2025Article
- Safety and tolerability of molnupiravir and nirmatrelvir/ritonavir in patients with advanced chronic kidney disease and kidney failure; a cohort study.Renal failure · 2025Article
- Clinical characteristics and risk factors associated with 28-day mortality among maintenance hemodialysis patients infected with Omicron variant of SARS-CoV-2.BMC infectious diseases · 2025Article
- Kidney involvement and anemia in COVID-19 infection.World journal of nephrology · 2025Review
- Humoral Response to the Third Dose of SARS-CoV-2 Vaccine Among Dialysis Patients: A Breakthrough Infection Case-Control Study.Vaccines · 2025Article
- Humoral Immune Responses in Dialysis Patients After mRNA Omicron JN.1 Vaccination.Kidney medicine · 2025Article
- Changes in Dialysis Practice Patterns in Australia and New Zealand During the COVID-19 Pandemic Period.Nephrology (Carlton, Vic.) · 2025Observational
- Patient Voices in Dialysis Care: Sentiment Analysis and Topic Modeling Study of Social Media Discourse.Journal of medical Internet research · 2025Article
- Article
- Evolving impact of the COVID-19 pandemic in chronic dialysis recipients in France.Communications medicine · 2025Article
- Risk factors for the mortality of hemodialysis patients with COVID-19 in northern Hunan province, China.BMC nephrology · 2025Article
- Status of COVID-19 vaccination in patients undergoing dialysis in China: a national cross-sectional study (2022).Frontiers in public health · 2025Article
- Research Trends in Proteomic Studies Using Serum from COVID-19 Patients: A Bibliometric Analysis.Current medicinal chemistry · 2025Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic has profound adverse effects on the population on dialysis. Patients requiring dialysis are at an increased risk of SARS-CoV-2 infection and mortality, and many have experienced psychological distress as well as delayed or suboptimal care. COVID-19 survivors have prolonged viral shedding, but generally develop a robust and long-lasting humoral immune response that correlates with initial disease severity. However, protection against reinfection is incomplete. A growing body of evidence reveals delayed and blunted immune responses to SARS-CoV-2 vaccination. Administration of a third dose within 1 to 2 months of prime-boost vaccination significantly increases antibody levels, in particular in patients with poor initial responses. Patients on dialysis have inferior immune responses to adenoviral vector vaccines than to mRNA vaccines. The immunogenicity of the mRNA-1273 vaccine is markedly better than that of the BNT162b2 vaccine, most likely by virtue of its higher mRNA content. Despite suboptimal immune responses in patients on dialysis, preliminary data suggest that vaccination partially protects against infection and severe disease requiring hospitalization. However, progressive waning of immunity and emergence of SARS-CoV-2 variants with a high potential of immune escape call for a booster dose in all patients on dialysis 4 to 6 months after prime-boost vaccination. Patients with persistent poor vaccine responses may be candidates for primary prophylaxis strategies. In the absence of specific data in patients on dialysis, therapeutic strategies in the event of established COVID-19 must be extrapolated from evidence obtained in the population not on dialysis. Neutralizing monoclonal antibodies may be an attractive option after a high-risk exposure or during the early course of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.